Aardvark Therapeutics, INC 8-K filings

Aardvark Therapeutics reported its second quarter 2026 financial results, highlighting a cash position supporting operations into late 2027, while addressing the clinical hold on its ARD-101 program and termination of related trials.

Aardvark Therapeutics announced a full clinical hold by the FDA on its investigational new drug application for ARD-101, impacting Phase 3 trials for Prader-Willi Syndrome.

Aardvark Therapeutics reported Q1 2026 results, revealing a significant increase in net loss and a voluntary pause on its ARD-101 and ARD-201 programs due to cardiac observations, with further guidance expected in Q2 2026.

Aardvark Therapeutics voluntarily paused its Phase 3 ARD-101 and Phase 2 ARD-201 trials due to unexpected reversible cardiac observations in a healthy volunteer study, while reporting increased net losses for 2025.

Aardvark Therapeutics has voluntarily paused its Phase 3 HERO trial for ARD-101 in Prader-Willi Syndrome due to reversible cardiac observations in a healthy volunteer study.

Aardvark Therapeutics establishes Ardia Therapeutics, a new dermatology subsidiary, and announces key leadership appointments including a new CEO for Ardia and an expanded role for its CFO.

Aardvark Therapeutics received IRB approval to lower the minimum age for its Phase 3 HERO trial of ARD-101 for Prader-Willi Syndrome from 10 to 7 years old.

Aardvark Therapeutics updated its corporate presentation, highlighting progress in its Prader-Willi Syndrome Phase 3 trial and advancing its obesity pipeline with two Phase 2 trials.

Aardvark Therapeutics announced the dosing of the first patient in Australia for its Phase 3 HERO trial of ARD-101 for Prader-Willi syndrome, maintaining its Q3 2026 data readout timeline.

Aardvark Therapeutics reported Q3 2025 financial results, expanded its PWS Phase 3 trial, and advanced its obesity drug candidate ARD-201 with promising preclinical data.

Aardvark Therapeutics hosted an investor webinar to detail progress on its ARD-101 and ARD-201 programs for rare metabolic diseases and obesity, alongside ObesityWeek 2025 presentations.

Aardvark Therapeutics presented positive preclinical and clinical data for its ARD-101, ARD-201, and WE-868 metabolic obesity programs at ObesityWeek 2025.

Aardvark Therapeutics announced FDA alignment on a protocol amendment to its Phase 3 HERO trial for Prader-Willi Syndrome, lowering the minimum age of eligibility from 13 to 10 years old.

Aardvark Therapeutics, Inc. updated its corporate presentation, highlighting pipeline advancements in rare metabolic diseases and obesity, with funding secured into 2027 and key data readouts anticipated.

Aardvark Therapeutics reported its second quarter 2025 financial results, highlighted by a $141.8 million cash position, expanded clinical trials for ARD-101, and new Phase 2 strategies for ARD-201 in obesity.

Aardvark Therapeutics announced positive preclinical data for ARD-201 in obesity, showing significant weight loss and enhanced GLP-1RA therapy, leading to plans for two new Phase 2 trials.

Aardvark Therapeutics announced its Q1 2025 financial results, highlighting $151.3 million in cash and progress on its Phase 3 HERO trial for ARD-101.

Aardvark Therapeutics announced its full year 2024 financial results, highlighting clinical progress with ARD-101 in Prader-Willi Syndrome and a successful IPO.

Aardvark Therapeutics finalized its IPO on February 14, 2025, and implemented amendments to its certificate of incorporation and bylaws to align with its new status as a public company.